Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial site itself and...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 November 2020
|
| In: |
BMC cancer
Year: 2020, Jahrgang: 20 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-020-07546-1 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12885-020-07546-1
|
| Verfasserangaben: | Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss and Johannes Ettl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 174775000X | ||
| 003 | DE-627 | ||
| 005 | 20250323014330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210208s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-020-07546-1 |2 doi | |
| 035 | |a (DE-627)174775000X | ||
| 035 | |a (DE-599)KXP174775000X | ||
| 035 | |a (OCoLC)1341391999 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hübner, Hanna |d 1987- |e VerfasserIn |0 (DE-588)1137635789 |0 (DE-627)89499798X |0 (DE-576)491675852 |4 aut | |
| 245 | 1 | 0 | |a Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany |c Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss and Johannes Ettl |
| 264 | 1 | |c 11 November 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.02.2021 | ||
| 520 | |a Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial site itself and is often a time-consuming procedure, which could result in missing out on potentially eligible patients. Pre-selection of those patients using a registry could facilitate the process of eligibility testing and increase the number of identified patients. One aim with the PRAEGNANT registry (NCT02338167) is to identify patients for therapies based on clinical and molecular data. Here, we report eligibility testing for the SHERBOC trial using the German PRAEGNANT registry. | ||
| 650 | 4 | |a Advanced breast cancer | |
| 650 | 4 | |a Antihormone therapy | |
| 650 | 4 | |a Heregulin | |
| 650 | 4 | |a Metastatic | |
| 650 | 4 | |a MM-121 | |
| 650 | 4 | |a Seribantumab | |
| 700 | 1 | |a Kurbacher, Christian M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuesters, Geoffrey |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hartkopf, Andreas D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lux, Michael P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Huober, Jens |e VerfasserIn |4 aut | |
| 700 | 1 | |a Volz, Bernhard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Taran, Florin-Andrei |e VerfasserIn |4 aut | |
| 700 | 1 | |a Overkamp, Friedrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tesch, Hans |e VerfasserIn |4 aut | |
| 700 | 1 | |a Häberle, Lothar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lüftner, Diana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wallwiener, Markus |d 1980- |e VerfasserIn |0 (DE-588)134044827 |0 (DE-627)692043934 |0 (DE-576)27468327X |4 aut | |
| 700 | 1 | |a Müller, Volkmar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beckmann, Matthias W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Belleville, Erik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ruebner, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Untch, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Fasching, Peter Andreas |d 1975- |e VerfasserIn |0 (DE-588)129068780 |0 (DE-627)388703040 |0 (DE-576)297477099 |4 aut | |
| 700 | 1 | |a Janni, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |8 2\p |a Fehm, Tanja |d 1971- |e VerfasserIn |0 (DE-588)120391759 |0 (DE-627)080645690 |0 (DE-576)292194064 |4 aut | |
| 700 | 1 | |a Kolberg, Hans-Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wallwiener, Diethelm |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brucker, Sara Y. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Ettl, Johannes |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 20(2020) Artikel-Nummer 1091, 13 Seiten |h Online-Ressource |w (DE-627)326643710 |w (DE-600)2041352-X |w (DE-576)107014645 |x 1471-2407 |7 nnas |a Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |a Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12885-020-07546-1 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20210208 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 25 | ||
| 998 | |g 134044827 |a Wallwiener, Markus |m 134044827:Wallwiener, Markus |d 910000 |d 910400 |d 50000 |e 910000PW134044827 |e 910400PW134044827 |e 50000PW134044827 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 13 | ||
| 999 | |a KXP-PPN174775000X |e 3849875407 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"174775000X","person":[{"given":"Hanna","display":"Hübner, Hanna","family":"Hübner","role":"aut"},{"role":"aut","family":"Kurbacher","display":"Kurbacher, Christian M.","given":"Christian M."},{"display":"Kuesters, Geoffrey","given":"Geoffrey","role":"aut","family":"Kuesters"},{"role":"aut","family":"Hartkopf","given":"Andreas D.","display":"Hartkopf, Andreas D."},{"role":"aut","family":"Lux","display":"Lux, Michael P.","given":"Michael P."},{"display":"Huober, Jens","given":"Jens","family":"Huober","role":"aut"},{"display":"Volz, Bernhard","given":"Bernhard","family":"Volz","role":"aut"},{"display":"Taran, Florin-Andrei","given":"Florin-Andrei","family":"Taran","role":"aut"},{"family":"Overkamp","role":"aut","display":"Overkamp, Friedrich","given":"Friedrich"},{"display":"Tesch, Hans","given":"Hans","role":"aut","family":"Tesch"},{"family":"Häberle","role":"aut","given":"Lothar","display":"Häberle, Lothar"},{"family":"Lüftner","role":"aut","display":"Lüftner, Diana","given":"Diana"},{"given":"Markus","display":"Wallwiener, Markus","family":"Wallwiener","role":"aut"},{"display":"Müller, Volkmar","given":"Volkmar","family":"Müller","role":"aut"},{"role":"aut","family":"Beckmann","given":"Matthias W.","display":"Beckmann, Matthias W."},{"display":"Belleville, Erik","given":"Erik","family":"Belleville","role":"aut"},{"role":"aut","family":"Ruebner","given":"Matthias","display":"Ruebner, Matthias"},{"given":"Michael","display":"Untch, Michael","family":"Untch","role":"aut"},{"display":"Fasching, Peter Andreas","given":"Peter Andreas","role":"aut","family":"Fasching"},{"given":"Wolfgang","display":"Janni, Wolfgang","role":"aut","family":"Janni"},{"role":"aut","family":"Fehm","given":"Tanja","display":"Fehm, Tanja"},{"family":"Kolberg","role":"aut","display":"Kolberg, Hans-Christian","given":"Hans-Christian"},{"role":"aut","family":"Wallwiener","display":"Wallwiener, Diethelm","given":"Diethelm"},{"given":"Sara Y.","display":"Brucker, Sara Y.","role":"aut","family":"Brucker"},{"family":"Schneeweiss","role":"aut","given":"Andreas","display":"Schneeweiss, Andreas"},{"family":"Ettl","role":"aut","given":"Johannes","display":"Ettl, Johannes"}],"note":["Gesehen am 08.02.2021"],"name":{"displayForm":["Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss and Johannes Ettl"]},"language":["eng"],"relHost":[{"language":["eng"],"part":{"text":"20(2020) Artikel-Nummer 1091, 13 Seiten","year":"2020","volume":"20"},"pubHistory":["1.2001 -"],"note":["Gesehen am 22.05.20"],"disp":"Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in GermanyBMC cancer","type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"326643710","title":[{"title":"BMC cancer","title_sort":"BMC cancer"}],"id":{"eki":["326643710"],"issn":["1471-2407"],"zdb":["2041352-X"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"London ; Berlin ; Heidelberg","dateIssuedKey":"2001","dateIssuedDisp":"2001-","publisher":"BioMed Central ; Springer"}]}],"origin":[{"dateIssuedDisp":"11 November 2020","dateIssuedKey":"2020"}],"title":[{"title_sort":"Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany","title":"Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["174775000X"],"doi":["10.1186/s12885-020-07546-1"]}} | ||
| SRT | |a HUEBNERHANHEREGULINH1120 | ||